Status:
UNKNOWN
Hyperintense: Midlife Hypertension and the Brain
Lead Sponsor:
Radboud University Medical Center
Conditions:
Hypertension
Small Vessel Cerebrovascular Disease
Eligibility:
All Genders
18-55 years
Brief Summary
Cerebral small vessel disease (SVD) describes a set of pathologies affecting the smallest blood vessels in the brain. SVD contributes to up to a fifth of ischemic and hemorrhagic strokes en is the mai...
Eligibility Criteria
Inclusion
- Study 1: cross-sectional study
- Age 18-40 years
- Blood pressure above 140/90 mmHg, measured within three months prior to study participation
Exclusion
- Pre-existing cerebrovascular disease
- Pregnancy
- Contraindications for 3 T MRI
- Renal function eGFR below 30 ml/min (for Dynamic Contrast Enhanced \[DCE\]-MRI
- Major risk factors for acute ischemic stroke other than SVD according to the TOAST criteria, including, but not limited to, large-artery atherosclerosis, cardioembolism and vasculitis based on medical history and ultrasound of the carotids collected at baseline or any chronic disease that could lead to brain lesions mimicking SVD
- Major (neurological/psychiatric) disease (e.g. multiple sclerosis)
- Not able to give informed consent
- Study 2: longitudinal study
- Inclusion criteria:
- Age 18-55 years
- Undergoing diagnostic routine of temporary antihypertensive withdrawal for biochemical analysis as part of clinical work-up
- Exclusion criteria:
- Pre-existing cerebrovascular disease
- Pregnancy
- Contraindications for 3 T MRI
- Renal function eGFR below 30 ml/min (for Dynamic Contrast Enhanced \[DCE\]-MRI
- Major risk factors for acute ischemic stroke other than SVD according to the TOAST criteria,22 including, but not limited to, large-artery atherosclerosis, cardioembolism and vasculitis based on medical history and ultrasound of the carotids collected at baseline or any chronic disease that could lead to brain lesions mimicking SVD
- Major (neurological/psychiatric) disease (e.g. multiple sclerosis)
- Not able to give informed consent
Key Trial Info
Start Date :
July 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT06175663
Start Date
July 6 2021
End Date
December 31 2023
Last Update
December 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RadboudUMC
Nijmegen, Netherlands, 6525GA Nijmegen